Anna Ossami Saidy on Muck Rack

Anna Ossami Saidy

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Anna Ossami

Contact Anna Ossami, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

The impact of IPI risk factors on CAR T-cell therapy or allogeneic stem cell transplantation for treatment of relapsed or refractory large B-cell lymphoma (LBCL)

|
By Anna Ossami Saidy, Ariane Boumendil, Peter Dreger, Federico Stella, Ron Ram, Nicolaus Kröger, Luca Castagna, Thomas Pabst, Gerald G. Wulf, Alejandro Martín García-Sancho, Carlos Solano, Matthias Stelljes, Hans Reinhardt, Edouard Forcade, Malte von Bonin, Inken Hilgendorf, Joaquín López, Wolfgang Andreas Bethge, Ali Bazarbachi, Anna Sureda, Norbert Schmitz, Bertram Glass
| Nature Verified
Abstract The International Prognostic Index (IPI) is an essential prognostic tool for patients with large B-cell lymphoma (LBCL). To compare outcomes after chimeric antigen receptor T-cell (CART) therapy and allogeneic stem cell transplantation (alloSCT) in relation to IPI risk factors, we analyzed 515 LBCL patients receiving CART (n = 303) or alloSCT (n = 212) as ≥third-line treatment, registered with EBMT (2016–2021).
Open in Who Shared Issue with article?

Chimeric antigen receptor T-cell therapy is equally effective and safe in older (≥70) and younger patients with multiple myeloma: a multicenter retrospective analysis

|
By Philipp Berning, Markus Maulhardt, Snjezana Janjetovic, Anna Ossami Saidy, Christian Schultze-Florey, Simon Call, Friedrich Stölzel, Annamaria Brioli, Michael Daskalakis, Rebecca I. Wurm-Kuczera, Matthias Stelljes, Cyrus Khandanpour, Ulrike Bacher, Amelie Boquoi, Florian H. Heidel, Hans Reinhardt, Gerald G. Wulf, Natalie Schub, Bastian von Tresckow, Georg Lenz, Thomas Pabst, Evgenii Shumilov, Hristo Boyadzhiev, Anca-Maria Albici, Juliane Knust, Justin Hasenkamp, Alexander Pohlmann
| Nature Verified
Dear Editor, The introduction of chimeric antigen receptor T-cell (CAR-T) therapies has significantly transformed the treatment landscape for patients with relapsed/refractory (r/r) multiple myeloma (MM). BCMA-directed CAR-T cell therapies, idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), have revolutionized the field by demonstrating remarkable efficacy in pivotal clinical trials [1, 2].
Open in Who Shared Issue with article?

Efficacy and safety of CAR T-cell therapy in patients with primary or secondary CNS lymphoma: A study on behalf of the EBMT and the GoCART coalition

|
By Christophe Peczynski, Catherine Thieblemont, Paris Sorbonne Cité, Anna Ossami Saidy
| tu-dresden.de
Abstract External IDs PubMedCentral PMC12093105
Open in Who Shared Issue with article?
See all 3 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified